文献速递甲状腺与浅表介入US

单次射频消融治疗持续性/复发性Graves病实现甲状腺功能正常化的初步研究

Efficacy of single-session radiofrequency ablation (RFA) in rendering euthyroidism for persistent/relapsed Graves' disease, a pilot study.
PubMed 文献 · Eur Radiol · 2023-04-10

该初步研究纳入15例持续性/复发性Graves病患者,接受超声引导下甲状腺射频消融,6个月和12个月缓解率分别为79.0%和73.3%,无严重并发症,提示单次RFA可能成为特定患者的治疗选择。

要点

  • 单次超声引导下甲状腺RFA可使部分持续性/复发性GD患者停用抗甲状腺药物后维持甲状腺功能正常。
  • RFA在门诊环境下耐受良好,未观察到声带麻痹、皮肤烧伤、血肿或甲状腺风暴。
  • 筛选患者需排除甲状腺叶体积≥20 mL、妊娠/哺乳期及严重合并症者。
英文原文(摘要)· 点击展开

OBJECTIVES: Graves' disease (GD) is the most common cause of hyperthyroidism. Antithyroid drug (ATD) is often the first-line treatment but > 50% patients suffer a relapse when ATD is discontinued. Surgery or radioiodine remains the current options of definitive treatment in these patients. This pilot study examined the short-term efficacy of single-session thyroid radiofrequency ablation (RFA) as a novel definitive treatment for persistent/relapsed GD.

METHODS: Consecutive patients with persistent/relapsed GD requiring ATD were considered. Those with a clear surgical indication, either thyroid lobe volume ≥ 20 mL; those who were pregnant or lactating; and those who had any severe medical conditions that would pose extra treatment risks were excluded. Eligible patients received ultrasound-guided RFA of the entire bulk of thyroid gland. Thyroid function tests were monitored bi-monthly. The primary outcome was disease remission rate, defined as a state of biochemical euthyroidism or hypothyroidism without ATD. Secondary outcomes were complication rates.

RESULTS: Of the 68 patients considered, 15 (22.1%) patients were eligible. Most were females (93.3%). The median age was 37 (IQR 31-48) years old. The disease remission rates were 79.0% at 6 months and 73.3% at 12 months. Among the 4 patients who relapsed after RFA, three required less ATD dose than before RFA. RFA was well-tolerated in the ambulatory setting. There were no vocal cord palsy, skin burn, hematoma, or thyroid storm after RFA.

CONCLUSIONS: In well-selected patients, single-session RFA of the thyroid gland may be a potential treatment for patients with persistent/relapsed GD. It is a safe and well-tolerated ambulatory procedure.

KEY POINTS: • Radiofrequency ablation of the thyroid gland is an efficacious treatment for persistent/relapsed Graves' disease in well-selected patients. • Radiofrequency ablation of the thyroid gland for the treatment of persistent/relapsed Graves' disease is a safe and well-tolerated ambulatory procedure. • Radiofrequency ablation of the thyroid gland may be a potential alternative treatment for well-selected patients with persistent/relapsed GD who do not wish to undergo either thyroidectomy or radioactive iodine or continue antithyroid drugs.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Fung, Lang. Efficacy of single-session radiofrequency ablation (RFA) in rendering euthyroidism for persistent/relapsed Graves' disease, a pilot study. Eur Radiol. 2023. PMID: 37036479. doi:10.1007/s00330-023-09620-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。